A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial

R. C. Bone, R. A. Balk, A. M. Fein, T. M. Perl, R. P. Wenzel, H. D. Reines, R. W. Quenzer, T. J. Iberti, N. Macintyre, Roland Schein, G. Trenholme, M. Niederman, D. Chalfin, P. Jebson, A. Abalos, J. Oropello, P. Empson, S. Caminitii, R. Greenman

Research output: Contribution to journalArticle

274 Citations (Scopus)

Abstract

Objective: To evaluate the safety and efficacy of E5, a murine, monoclonal antibody directed against endotoxin, in the treatment of patients with Gram- negative sepsis. Design: A multicenter, randomized, double-blind, placebo- controlled trial. Setting: Fifty-three hospitals across the United States, including university medical centers, Veterans Affairs Medical Centers, and community hospitals. Patients: 847 patients were randomized into this study. Enrolled patients met criteria for three conditions: a) known or suspected Gram-negative infection; b) clinical evidence of sepsis; and c) signs of end- organ dysfunction. Patients with refractory shock were excluded from the study. Interventions: Two doses of E5 (2 mg/kg/day by intravenous infusion 24 hrs apart), or placebo that was identical in appearance were administered. In addition, all patients received standard supportive therapy and broad- spectrum antibiotics. Measurements and Main Results: The primary end point was mortality over 30 days. Secondary outcome measures included the resolution and prevention of organ failure in the same two populations. Additionally, the safety of E5 was evaluated. There was no significant improvement in survival over 30 days among patients with Gram-negative sepsis who received E5 compared with those patients who received placebo (n = 530;p = .21). In addition, E5 did not improve survival for patients with Gram- negative sepsis and organ failure (n = 139;p = .3). However, a significantly greater percentage of patients with Gram-negative sepsis experienced resolution of major organ failure if they received E5, compared with those patients who received placebo (n = 139; 48% E5 vs. 25% placebo; p = .005). This result extended to all patients who entered the study with one or more major organ failures, regardless of the etiology of the infection (n = 225; 41% E5 vs. 27% placebo; p = .024). E5 also provided protection against the development of some organ failures, but significant prevention was only observed for adult respiratory distress syndrome (p = .007) and central nervous system dysfunction (p = .050). Hypersensitivity reactions attributable to E5 occurred in 2.6% of patients. An asymptomatic antibody response occurred in 44% of the E5-treated patients and in 12% of the patients who received placebo. Conclusions: In this study, E5 did not reduce mortality in nonshock patients with Gram-negative sepsis whether or not those patients also had organ failure. However, E5 did result in greater resolution of organ failure in patients with Gram-negative sepsis. This benefit extended to those patients with suspected Gram-negative etiology. This finding is important because patients with suspected Gram-negative sepsis and organ failure can be identified without waiting for culture results. In addition, E5 resulted in the prevention of adult respiratory distress syndrome and central nervous system organ failure. However, more studies are needed to determine if this result can be extended to organ failure in general. E5 is safe as a treatment for patients with Gram-negative sepsis.

Original languageEnglish
Pages (from-to)994-1006
Number of pages13
JournalCritical Care Medicine
Volume23
Issue number6
DOIs
StatePublished - Jun 26 1995
Externally publishedYes

Fingerprint

Endotoxins
Randomized Controlled Trials
Sepsis
Placebos
edobacomab
Clinical Studies
Adult Respiratory Distress Syndrome
Central Nervous System
Safety
Survival
Mortality
Community Hospital
Veterans
Infection

Keywords

  • bacteremia
  • critical illness
  • endotoxemia
  • endotoxin
  • Gram-negative bacteria
  • interleukin-1
  • monoclonal antibody
  • randomized clinical trial
  • sepsis
  • tumor necrosis factor

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin : Results of a prospective, multicenter, randomized, controlled trial. / Bone, R. C.; Balk, R. A.; Fein, A. M.; Perl, T. M.; Wenzel, R. P.; Reines, H. D.; Quenzer, R. W.; Iberti, T. J.; Macintyre, N.; Schein, Roland; Trenholme, G.; Niederman, M.; Chalfin, D.; Jebson, P.; Abalos, A.; Oropello, J.; Empson, P.; Caminitii, S.; Greenman, R.

In: Critical Care Medicine, Vol. 23, No. 6, 26.06.1995, p. 994-1006.

Research output: Contribution to journalArticle

Bone, RC, Balk, RA, Fein, AM, Perl, TM, Wenzel, RP, Reines, HD, Quenzer, RW, Iberti, TJ, Macintyre, N, Schein, R, Trenholme, G, Niederman, M, Chalfin, D, Jebson, P, Abalos, A, Oropello, J, Empson, P, Caminitii, S & Greenman, R 1995, 'A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial', Critical Care Medicine, vol. 23, no. 6, pp. 994-1006. https://doi.org/10.1097/00003246-199506000-00003
Bone, R. C. ; Balk, R. A. ; Fein, A. M. ; Perl, T. M. ; Wenzel, R. P. ; Reines, H. D. ; Quenzer, R. W. ; Iberti, T. J. ; Macintyre, N. ; Schein, Roland ; Trenholme, G. ; Niederman, M. ; Chalfin, D. ; Jebson, P. ; Abalos, A. ; Oropello, J. ; Empson, P. ; Caminitii, S. ; Greenman, R. / A second large controlled clinical study of E5, a monoclonal antibody to endotoxin : Results of a prospective, multicenter, randomized, controlled trial. In: Critical Care Medicine. 1995 ; Vol. 23, No. 6. pp. 994-1006.
@article{d56ef081530e4032a828bca275e4fa59,
title = "A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial",
abstract = "Objective: To evaluate the safety and efficacy of E5, a murine, monoclonal antibody directed against endotoxin, in the treatment of patients with Gram- negative sepsis. Design: A multicenter, randomized, double-blind, placebo- controlled trial. Setting: Fifty-three hospitals across the United States, including university medical centers, Veterans Affairs Medical Centers, and community hospitals. Patients: 847 patients were randomized into this study. Enrolled patients met criteria for three conditions: a) known or suspected Gram-negative infection; b) clinical evidence of sepsis; and c) signs of end- organ dysfunction. Patients with refractory shock were excluded from the study. Interventions: Two doses of E5 (2 mg/kg/day by intravenous infusion 24 hrs apart), or placebo that was identical in appearance were administered. In addition, all patients received standard supportive therapy and broad- spectrum antibiotics. Measurements and Main Results: The primary end point was mortality over 30 days. Secondary outcome measures included the resolution and prevention of organ failure in the same two populations. Additionally, the safety of E5 was evaluated. There was no significant improvement in survival over 30 days among patients with Gram-negative sepsis who received E5 compared with those patients who received placebo (n = 530;p = .21). In addition, E5 did not improve survival for patients with Gram- negative sepsis and organ failure (n = 139;p = .3). However, a significantly greater percentage of patients with Gram-negative sepsis experienced resolution of major organ failure if they received E5, compared with those patients who received placebo (n = 139; 48{\%} E5 vs. 25{\%} placebo; p = .005). This result extended to all patients who entered the study with one or more major organ failures, regardless of the etiology of the infection (n = 225; 41{\%} E5 vs. 27{\%} placebo; p = .024). E5 also provided protection against the development of some organ failures, but significant prevention was only observed for adult respiratory distress syndrome (p = .007) and central nervous system dysfunction (p = .050). Hypersensitivity reactions attributable to E5 occurred in 2.6{\%} of patients. An asymptomatic antibody response occurred in 44{\%} of the E5-treated patients and in 12{\%} of the patients who received placebo. Conclusions: In this study, E5 did not reduce mortality in nonshock patients with Gram-negative sepsis whether or not those patients also had organ failure. However, E5 did result in greater resolution of organ failure in patients with Gram-negative sepsis. This benefit extended to those patients with suspected Gram-negative etiology. This finding is important because patients with suspected Gram-negative sepsis and organ failure can be identified without waiting for culture results. In addition, E5 resulted in the prevention of adult respiratory distress syndrome and central nervous system organ failure. However, more studies are needed to determine if this result can be extended to organ failure in general. E5 is safe as a treatment for patients with Gram-negative sepsis.",
keywords = "bacteremia, critical illness, endotoxemia, endotoxin, Gram-negative bacteria, interleukin-1, monoclonal antibody, randomized clinical trial, sepsis, tumor necrosis factor",
author = "Bone, {R. C.} and Balk, {R. A.} and Fein, {A. M.} and Perl, {T. M.} and Wenzel, {R. P.} and Reines, {H. D.} and Quenzer, {R. W.} and Iberti, {T. J.} and N. Macintyre and Roland Schein and G. Trenholme and M. Niederman and D. Chalfin and P. Jebson and A. Abalos and J. Oropello and P. Empson and S. Caminitii and R. Greenman",
year = "1995",
month = "6",
day = "26",
doi = "10.1097/00003246-199506000-00003",
language = "English",
volume = "23",
pages = "994--1006",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A second large controlled clinical study of E5, a monoclonal antibody to endotoxin

T2 - Results of a prospective, multicenter, randomized, controlled trial

AU - Bone, R. C.

AU - Balk, R. A.

AU - Fein, A. M.

AU - Perl, T. M.

AU - Wenzel, R. P.

AU - Reines, H. D.

AU - Quenzer, R. W.

AU - Iberti, T. J.

AU - Macintyre, N.

AU - Schein, Roland

AU - Trenholme, G.

AU - Niederman, M.

AU - Chalfin, D.

AU - Jebson, P.

AU - Abalos, A.

AU - Oropello, J.

AU - Empson, P.

AU - Caminitii, S.

AU - Greenman, R.

PY - 1995/6/26

Y1 - 1995/6/26

N2 - Objective: To evaluate the safety and efficacy of E5, a murine, monoclonal antibody directed against endotoxin, in the treatment of patients with Gram- negative sepsis. Design: A multicenter, randomized, double-blind, placebo- controlled trial. Setting: Fifty-three hospitals across the United States, including university medical centers, Veterans Affairs Medical Centers, and community hospitals. Patients: 847 patients were randomized into this study. Enrolled patients met criteria for three conditions: a) known or suspected Gram-negative infection; b) clinical evidence of sepsis; and c) signs of end- organ dysfunction. Patients with refractory shock were excluded from the study. Interventions: Two doses of E5 (2 mg/kg/day by intravenous infusion 24 hrs apart), or placebo that was identical in appearance were administered. In addition, all patients received standard supportive therapy and broad- spectrum antibiotics. Measurements and Main Results: The primary end point was mortality over 30 days. Secondary outcome measures included the resolution and prevention of organ failure in the same two populations. Additionally, the safety of E5 was evaluated. There was no significant improvement in survival over 30 days among patients with Gram-negative sepsis who received E5 compared with those patients who received placebo (n = 530;p = .21). In addition, E5 did not improve survival for patients with Gram- negative sepsis and organ failure (n = 139;p = .3). However, a significantly greater percentage of patients with Gram-negative sepsis experienced resolution of major organ failure if they received E5, compared with those patients who received placebo (n = 139; 48% E5 vs. 25% placebo; p = .005). This result extended to all patients who entered the study with one or more major organ failures, regardless of the etiology of the infection (n = 225; 41% E5 vs. 27% placebo; p = .024). E5 also provided protection against the development of some organ failures, but significant prevention was only observed for adult respiratory distress syndrome (p = .007) and central nervous system dysfunction (p = .050). Hypersensitivity reactions attributable to E5 occurred in 2.6% of patients. An asymptomatic antibody response occurred in 44% of the E5-treated patients and in 12% of the patients who received placebo. Conclusions: In this study, E5 did not reduce mortality in nonshock patients with Gram-negative sepsis whether or not those patients also had organ failure. However, E5 did result in greater resolution of organ failure in patients with Gram-negative sepsis. This benefit extended to those patients with suspected Gram-negative etiology. This finding is important because patients with suspected Gram-negative sepsis and organ failure can be identified without waiting for culture results. In addition, E5 resulted in the prevention of adult respiratory distress syndrome and central nervous system organ failure. However, more studies are needed to determine if this result can be extended to organ failure in general. E5 is safe as a treatment for patients with Gram-negative sepsis.

AB - Objective: To evaluate the safety and efficacy of E5, a murine, monoclonal antibody directed against endotoxin, in the treatment of patients with Gram- negative sepsis. Design: A multicenter, randomized, double-blind, placebo- controlled trial. Setting: Fifty-three hospitals across the United States, including university medical centers, Veterans Affairs Medical Centers, and community hospitals. Patients: 847 patients were randomized into this study. Enrolled patients met criteria for three conditions: a) known or suspected Gram-negative infection; b) clinical evidence of sepsis; and c) signs of end- organ dysfunction. Patients with refractory shock were excluded from the study. Interventions: Two doses of E5 (2 mg/kg/day by intravenous infusion 24 hrs apart), or placebo that was identical in appearance were administered. In addition, all patients received standard supportive therapy and broad- spectrum antibiotics. Measurements and Main Results: The primary end point was mortality over 30 days. Secondary outcome measures included the resolution and prevention of organ failure in the same two populations. Additionally, the safety of E5 was evaluated. There was no significant improvement in survival over 30 days among patients with Gram-negative sepsis who received E5 compared with those patients who received placebo (n = 530;p = .21). In addition, E5 did not improve survival for patients with Gram- negative sepsis and organ failure (n = 139;p = .3). However, a significantly greater percentage of patients with Gram-negative sepsis experienced resolution of major organ failure if they received E5, compared with those patients who received placebo (n = 139; 48% E5 vs. 25% placebo; p = .005). This result extended to all patients who entered the study with one or more major organ failures, regardless of the etiology of the infection (n = 225; 41% E5 vs. 27% placebo; p = .024). E5 also provided protection against the development of some organ failures, but significant prevention was only observed for adult respiratory distress syndrome (p = .007) and central nervous system dysfunction (p = .050). Hypersensitivity reactions attributable to E5 occurred in 2.6% of patients. An asymptomatic antibody response occurred in 44% of the E5-treated patients and in 12% of the patients who received placebo. Conclusions: In this study, E5 did not reduce mortality in nonshock patients with Gram-negative sepsis whether or not those patients also had organ failure. However, E5 did result in greater resolution of organ failure in patients with Gram-negative sepsis. This benefit extended to those patients with suspected Gram-negative etiology. This finding is important because patients with suspected Gram-negative sepsis and organ failure can be identified without waiting for culture results. In addition, E5 resulted in the prevention of adult respiratory distress syndrome and central nervous system organ failure. However, more studies are needed to determine if this result can be extended to organ failure in general. E5 is safe as a treatment for patients with Gram-negative sepsis.

KW - bacteremia

KW - critical illness

KW - endotoxemia

KW - endotoxin

KW - Gram-negative bacteria

KW - interleukin-1

KW - monoclonal antibody

KW - randomized clinical trial

KW - sepsis

KW - tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0029043636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029043636&partnerID=8YFLogxK

U2 - 10.1097/00003246-199506000-00003

DO - 10.1097/00003246-199506000-00003

M3 - Article

C2 - 7774238

AN - SCOPUS:0029043636

VL - 23

SP - 994

EP - 1006

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 6

ER -